血清sFlt-1和PlGF联合检测对妊娠期急性脂肪肝病情严重程度和疾病预后的评估价值

摘要/Abstract

摘要： 目的探讨可溶性fms样酪氨酸激酶-1(sFlt-1)和胎盘生长因子(PlGF)水平联合检测对妊娠期急性脂肪肝(AFLP)病情程度和预后评估的价值。方法选择2018年1月—2021年7月收治的AFLP患者35例列入观察组,根据凝血酶原活动度(PTA)水平分为轻型组和重型组,根据治愈时间分为易治愈组和难治愈组。选择同期健康孕产妇35例,列入对照组。比较观察组和对照组的血清sFlt-1、PlGF、PBG、Alb、TBil、PT和Cr水平;比较观察组中不同病情程度和不同治愈时间亚组的血清sFlt-1和PlGF水平;比较血清sFlt-1和PlGF水平与PBG、Alb、TBil、PT和Cr水平的相关性,回归分析单独检测和联合检测sFlt-1和PlGF水平的诊断效能。结果观察组的血清sFlt-1水平为(3 829.57 ± 506.41) pg/mL,高于对照组的(516.48 ± 87.25)pg/mL,PlGF水平为(152.64 ± 35.17) pg/mL,低于对照组的(375.62 ± 74.38) pg/mL,差异有统计学意义(t=187.258, 16.492, P<0.05)。观察组的TBil、Cr和PT水平显著高于对照组,PBG和Alb水平低于对照组(P<0.05)。观察组中,重症和难治愈亚组的血清sFlt-1水平[(5 024.86 ± 638.57 )pg/mL, 4 659.27 ± 471.83 pg/mL]分别高于轻症亚组[(2 908.59 ± 304.80)pg/mL, (3 260.85 ± 369.42) pg/mL],差异有统计学意义(t=25.385, 19.473, P<0.05);PlGF水平[(98.38 ± 27.35)pg/mL, (107.34 ± 29.68) pg/mL]分别低于轻症和易治愈亚组[(187.45 ± 48.61) pg/mL, (172.56 ± 45.19)pg/mL],差异有统计学意义(t=19.276, 14.725, P<0.05)。Pearson分析显示,AFLP患者的血清sFlt-1水平与PBG和Alb水平呈负相关,与TBil、Cr和PT水平呈正相关(P<0.05);血清PlGF水平与PBG和Alb水平呈正相关,与TBil、Cr和PT水平呈负相关(P<0.05)。ROC曲线显示,sFlt-1和PlGF水平单独和联合检测诊断AFLP的曲线下面积(AUC)分别为0.925、0.903和0.976,联合检测的效能显著高于任一单项检测(P<0.05)。结论血清sFlt-1和PlGF水平对AFLP患者病情严重程度和预后评估的临床价值较高,联合检测的效能更佳。

关键词: 妊娠期急性脂肪肝, 可溶性fms样酪氨酸激酶-1, 胎盘生长因子, 预后

Abstract: Objective To explore the value of combined detection of soluble FMS like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) in evaluating the severity and prognosis of acute fatty liver during pregnancy (AFLP).Methods 35 AFLP patients admitted from January 2018 to July 2021 were included in the observation group. According to the level of prothrombin activity (PTA), they were divided into mild group and severe group, and were divided into easy to cure group and difficult to cure group according to the cure time. Thirty-five healthy pregnant women were included in the control group. The serum levels of sFlt-1, PlGF, postprandial blood glucose (PBG), albumin (Alb), total bilirubin (TBil), prothrombin time (PT) and creatinine (Cr) in the observation group and the control group were compared. The levels of serum sFlt-1 and PlGF in subgroups with different severity of disease and different cure time were compared. The correlation between serum sFlt-1 and PlGF levels and PBG, Alb, TBil, PT and Cr levels was compared, and the diagnostic efficacy of sFlt-1 and PlGF levels alone and combined detection was analyzed by regression analysis.Results The serum sFlt-1 level in the observation group (3829.57±506.41 pg/mL) was higher than that in the control group (516.48±87.25 pg/mL), and the serum PlGF level (152.64±35.17 pg/mL) was lower than that in the control group (375.62±74.38 pg/mL). The difference was statistically significant (t=187.258, 16.492, P<0.05). The levels of TBil, Cr and PT in observation group were significantly higher than those in control group, while the levels of PBG and Alb were lower than those in control groups (P<0.05). In the observation group, the serum sFlt-1 levels of severe and difficult to cure groups (5024.86±638.57 pg/mL, 4659.27±471.83 pg/mL) were higher than those of mild and easy to cure groups (2908.59±304.80 pg/mL, 3260.85±369.42 pg/mL), respectively, and the difference was statistically significant (t=25.385, 19.473, P<0.05). PlGF levels (98.38±27.35 pg/mL, 107.34±29.68 pg/mL) were lower than those of mild and difficult to cure groups (187.45±48.61 pg/mL, 172.56±45.19 pg/mL), and the difference was statistically significant (t=19.276, 14.725, P<0.05). Pearson analysis showed that the serum sFlt-1 level of AFLP patients was negatively correlated with PBG and Alb levels, but positively correlated with TBil, Cr and PT levels (P<0.05). Serum PlGF levels were positively correlated with PBG and Alb levels, but negatively correlated with TBil, Cr and PT levels (P<0.05). Receiver operating characteristic (ROC) curve showed that the area under curve (AUC) of sFlt-1, PlGF and combined detection for AFLP diagnosis were 0.925, 0.903 and 0.976, respectively, indicating that combined detection was significantly more efficient than any single detection (P<0.05).Conclusion Serum sFlt-1 and PlGF levels have higher clinical value in evaluating the severity and prognosis of AFLP patients, and the combined detection is more effective.

Key words: Acute fatty liver in pregnancy, sFlt-1, PlGF, Prognosis

张文婷, 徐晓英, 卢蓉. 血清sFlt-1和PlGF联合检测对妊娠期急性脂肪肝病情严重程度和疾病预后的评估价值[J]. 肝脏, 2022, 27(8): 915-919.

ZHANG Wen-ting, XU Xiao-ying, LU Rong. Clinical value of combined detection of serum sFlt-1 and PlGF levels on severity and prognosis of acute fatty liver disease in pregnancy[J]. Chinese Hepatolgy, 2022, 27(8): 915-919.

参考文献

[1] Chen GZ, Huang K, Ji BR, et al. Acute fatty liver of pregnancy in a Chinese Tertiary Care Center:a retrospective study. Arch Gynecol Obstet, 2019, 4: 897-901.
[2] 付丽华, 曹彦君, 王晓娟, 等. 影响妊娠急性脂肪肝患者治愈时间的危险因素. 中国肝脏病杂志, 2021, 2: 52-57.
[3] Phuoung V, AreerukW, Tantbirojn P, et al. Soluble fms-like tyrosine kinase 1 and placental growth factor ratio for predicting preeclampsia in elderly gravida. Hypertens Pregnancy, 2020, 2: 139-144.
[4] 周霞. 胎盘生长因子:治疗肝肺综合征的新靶点. 肝脏, 2018, 11: 955-956.
[5] Enengl S, Mayer RB, Le Renard PE, et al. Retrospective evaluation of established cut-off values for the sFlt-1/PlGF ratio for predicting imminent delivery in preeclampsia patients. Pregnancy Hypertens, 2020, 19: 143-149.
[6] 熊号峰, 刘景院, 李传胜, 等. Swansea诊断标准在妊娠急性脂肪肝中的应用价值. 中国肝脏病杂志, 2017, 3: 40-44.
[7] 孙秀荣, 张杰生, 苏放明. 妊娠期急性脂肪肝42例临床分析. 国际医药卫生导报, 2020, 20: 3092-3094.
[8] 赵桂芳. 妊娠急性脂肪肝患者应用非生物型人工肝支持技术的疗效及不良反应观察. 肝脏, 2017, 7: 610-613.
[9] 周敏, 罗小东, 杨洋. 54例妊娠急性脂肪肝患者临床特点和实验室指标变化分析. 中华肝脏病杂志, 2019, 8: 638-642.
[10] Muoz HR, Medrano CP, Miranda ML, et al. Total and fetal circulating cell-free DNA, angiogenic, and antiangiogenic factors in preeclampsia and HELLP syndrome. Am J Hypertens, 2017, 30: 673-682.
[11] Neuman RI, Hesselink ERM, Saleh L, et al. Angiogenic markers are elevated in women with acute fatty liver of pregnancy. Ultrasound Obstet Gynecol, 2020, 56: 465-466.
[12] Muhammad IAA, Indah MS, Aditiawarman, et al. Clinical characteristics of acute fatty liver of pregnancy in a tertiary Indonesian hospital. J Matern Fetal Neonatal Med, 2019, 5: 826-832.
[13] Brady CW. Liver disease in pregnancy: What's new. Hepatol Commun, 2020, 4: 145-156.
[14] 金莉娅, 李慧敏, 吕玲, 等. 重度子痫前期孕妇血清VEGF、sFlt-1及IGF-1水平与围生儿结局的关系研究. 中国妇幼保健, 2019, 9: 1977-1979.
[15] Oe Y, Ko M, Fushima T, et al. Hepatic dysfunction and thrombocytopenia induced by excess sFlt1 in mice lacking endothelial nitric oxide synthase. Sci Rep, 2018, 1: 359-371.
[16] 童婷婷, 虞晴, 尤子善, 等. 子痫前期孕妇血浆蛋白酶Corin、PIGF、sEng、sFlt-1水平变化及临床意义. 中国妇产科临床杂志, 2021, 3: 285-286.
[17] Trottmann F, Raio L, AmylidiMohr S, et al. Soluble fms‐like tyrosine kinase 1 (sFlt‐1): A novel biochemical marker for acute fatty liver of pregnancy. Acta Obstet Gynecol Scand, 2021, 10: 1876-1884.
[18] Herraiz I, Quezada MS, Rodriguez-Calvo J, et al. P018: Longitu- dinal change of sFlt-1 /PlGF ratio in singleton pregnancy with early-onset fetal growth restriction. Ultrasound Obstet Gynecol, 2018, 5: 631-638.
[19] 李岩, 鲁翠萍, 彭菊兰, 等. 重度子痫前期患者血清sFlt-1、PLGF水平与妊娠结局的相关性. 海南医学, 2021, 16: 2091-2093.
[20] Suzuki H, Nagayama S, Hirashima C, et al. Markedly higher sFlt-1/PlGF ratio in a woman with acute fatty liver of pregnancy compared with HELLP syndrome. J Obstet Gynaecol Res,2019,45: 96-103.
[21] 李朝曦. 子痫前期患者血清sFlt-1、PLGF水平预测胎儿宫内生长受限的临床研究. 医药论坛杂志, 2021, 42(8): 83-86.